Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Signed informed consent

• Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at least 2 years.

• Clinically stable and in an outpatient setting before entering the study (visit 1).

Exclusion Criteria:

• Use of clozapine and quetiapine within two months prior to visit 1.

• If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III test at visit 1.